Kestra Advisory Services LLC Invests $64,000 in Candel Therapeutics, Inc. (NASDAQ:CADL)

Kestra Advisory Services LLC bought a new stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADLGet Rating) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,500 shares of the company’s stock, valued at approximately $64,000.

Separately, 683 Capital Management LLC purchased a new stake in Candel Therapeutics during the 4th quarter valued at about $320,000. Institutional investors and hedge funds own 24.23% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets dropped their target price on Candel Therapeutics from $18.00 to $12.00 and set an “outperform” rating for the company in a report on Thursday, March 31st.

Candel Therapeutics Trading Up 4.3 %

CADL opened at $3.40 on Thursday. The business has a 50 day simple moving average of $3.49 and a two-hundred day simple moving average of $4.25. The firm has a market capitalization of $97.56 million and a price-to-earnings ratio of -1.60. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.48 and a quick ratio of 17.48. Candel Therapeutics, Inc. has a one year low of $2.81 and a one year high of $14.78.

Candel Therapeutics (NASDAQ:CADLGet Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.46. Candel Therapeutics had a negative return on equity of 29.17% and a negative net margin of 29,132.26%. Analysts predict that Candel Therapeutics, Inc. will post -1.92 EPS for the current year.

Candel Therapeutics Profile

(Get Rating)

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

Featured Stories

Want to see what other hedge funds are holding CADL? Visit to get the latest 13F filings and insider trades for Candel Therapeutics, Inc. (NASDAQ:CADLGet Rating).

Institutional Ownership by Quarter for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with's FREE daily email newsletter.